Columbia's drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

Drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

Cox Enterprises formed part of a consortium that provided $126m for Iora Health, a healthcare provider whose investors also include Humana and General Electric.

Illumina Ventures returned to reinvest in a $21.8m round for the DNA-analysis system developer having led its series A round in 2018.

Paris Saclay Seed Fund and all other existing backers returned for the series B round, which additionally attracted Tsinghua University’s TUS Holdings.

Sonoma Biotherapeutics has emerged from stealth with $40m to develop regulatory T-cell therapies for autoimmune and degenerative diseases.

Sonoma Biotherapeutics has emerged from stealth with $40m from investors including Lyell Immunopharma and is developing regulatory T-cell therapies for autoimmune and degenerative diseases.

Biocodex returned for a $19.8m round that boosted microbiome drug developer MaaT Pharma's overall funding to more than $33m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.